Calidi Biotherapeutics, Inc. · AMEX:CLDI

Calidi Biotherapeutics — Investor Presentation (April 2026)

13 slides from Calidi Biotherapeutics's investor presentation, April 2026

  1. Slide 1: Engineering the Future of Genetic Medicine

    Immune Genetic Protection Medicine(s) Engineering the Future of Genetic Medicine Targeting From cancer to other complex diseases, Calidi’s RedTail platform can precisely deliver genetic medicine to distal sites of disease Self-amplifying April 2026 selective vector Platform NYSE American: CLDI Calid

  2. Slide 2: Calidi Biotherapeutics: precise delivery of genetic medicine to the site of disease

    Calidi Biotherapeutics: precise delivery of genetic medicine to the site of disease Calidi Biotherapeutics The RedTail Platform (NYSE American: CLDI) Immune  Engineering the Future of Genetic Genetic Medicine(s) Protection Medicine to treat cancer and complex disease – Calidi technology expresses h

  3. Slide 3: Efficacy Established with Intra-Tumoral Oncolytic Viruses: Systemic Delivery Would Expand Access to Most Patients

    Efficacy Established with Intra-Tumoral Oncolytic Viruses: Systemic Delivery Would Expand Access to Most Patients Legacy Attempts / Local Efficacy Calidi’s Systemic Solution  Multiple examples of efficacy with  The challenge: the immune system local administration clears systemically injected viru

  4. Slide 4: Building the RedTail Scaffold: Step 1 Tumor Tropism

    Building the RedTail Scaffold: Step 1 Tumor Tropism  Tumor Tropism and Replication Selectivity – Vaccinia virus has inherent tropism for tumor cells1 – Vaccinia virus cell entry is not receptor dependent2  Virus genetically engineered to replicate only in tumor cells – Triple knockout version of v

  5. Slide 5: Building the RedTail Scaffold: Step 2 Genetic Medicine Payload

    Building the RedTail Scaffold: Step 2 Genetic Medicine Payload Genetic Medicine(s)  Genetic Medicine Payload – Vaccinia has a large genome with high capacity for insertion(s)1 • ~200kbp with >200 ORFs; up to 25kbp capacity for insertion – Calidi has identified proprietary sites in RedTail for gene(

  6. Slide 6: Building the RedTail Scaffold: Step 3 Viral Envelope

    Building the RedTail Scaffold: Step 3 Viral Envelope Envelope  Enveloped Form of Vaccinia Virus – Vaccinia virus produces two forms of infectious particles1 • During infection, >99% of virus is Intracellular Mature Virus (IMV) • <1% of virus is the Extracellular Enveloped Virus (EEV) form that take

  7. Slide 7: Building the RedTail Scaffold: Step 4 CD55 Overexpression

    CD55 Building the RedTail Scaffold: Step 4 CD55 Overexpression  CD55 Overexpression – Complement is pivotal for immune clearance for Vaccinia1,2 • Complement is the major mechanism for clearance of Vaccinia3 – CD55 expression inhibits complement activation4 • RedTail scaffold genetically engineered

  8. Slide 8: CLD-401: The First Lead From the RedTail Platform

    CLD-401: The First Lead From the RedTail Platform  Systemic administration  Protected from immune clearance (EEV/CD55)  Targeted tumor cell lysis and immune priming  IL-15 superagonist production at the tumor  Induces innate and adaptive response to the tumor IND filing expected 2026; Phase I m

  9. Slide 9: CLD-401: Tumor-specific IL-15SA expression

    CLD-401: Tumor-specific IL-15SA expression  IL-15 SA concentrations in the tumor are similar to concentrations with locally- administered Anktiva in bladder cancer – Expression in serum or other tissues is >1,000 times lower IL-15 SA concentrations (pM) in tumor and organs at multiple time points T

  10. Slide 10: Enhanced Therapeutic Activity With In Situ IL-15 SA Expression

    Enhanced Therapeutic Activity With In Situ IL-15 SA Expression RedTail virus with IL-15 SA payload (CLD-401) dramatically improves treatment efficacy Tumor regression in syngeneic EMT6 model after a single administration of 5x106 PFU viral particles Untreated RedTail Virus (no payload) CLD-401 (IL-1

  11. Slide 11: RedTail: Potential to Enhance Platform and Expand Outside of Oncology

    RedTail: Potential to Enhance Platform and Expand Outside of Oncology Next-Generations  Cancer: – Expand payload options – up to three genetic payloads – Proof-of-concept established with in situ TCEs: simultaneous expression of a T-cell engager and a T-cell activating genetic payload(s) – Engineer

  12. Slide 12: Expanding the RedTail Platform: In Situ T-Cell Engagers

    Expanding the RedTail Platform: In Situ T-Cell Engagers T-cell engagers (TCEs) have faced In Situ T-cell Engagers were specifically designed using the obstacles in the treatment of solid tumors RedTail platform to overcome these challenges 1 RedTail is only active in In situ tumor cells, limiting th

  13. Slide 13: Calidi’s Partnership / Licensing Goals

    Calidi’s Partnership / Licensing Goals Immune Genetic Protection  Mutual opportunity in collaboration Medicine(s)  Calidi seeks partners with expertise in oncology or autoimmune disease to expand the reach of its RedTail platform  Calidi can design vectors – Targeted to a specific extracellular m

Calidi Biotherapeutics — Investor Presentation (April 2026) on 6ix